{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gram+Positive+Bacterial+Infection&page=24",
    "query": {
      "condition": "Gram Positive Bacterial Infection",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 779,
    "total_pages": 78,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gram+Positive+Bacterial+Infection&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gram+Positive+Bacterial+Infection&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T07:30:45.364Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06262282",
      "title": "Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis",
        "Nontuberculous Mycobacterial Lung Disease",
        "Nontuberculous Mycobacterium Infection",
        "Mycobacterium Infections",
        "Mycobacterium; Pulmonary"
      ],
      "interventions": [
        {
          "name": "mycobacteriophage",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-02-05",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06262282"
    },
    {
      "nct_id": "NCT01404312",
      "title": "Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Rifapentine (RPT)",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid (INH)",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine (Vitamin B6)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2012-05-23",
      "completion_date": "2017-11-14",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 21,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01404312"
    },
    {
      "nct_id": "NCT00000971",
      "title": "The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mycobacterium Avium-intracellulare Infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Clarithromycin",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 24,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-08-04",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Bethesda, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000971"
    },
    {
      "nct_id": "NCT03783728",
      "title": "Video Based Directly Observed Therapy for Latent TB",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Latent Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifapentine 600 mg orally",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid 900 mg orally",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine 50 mg orally",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-30",
      "completion_date": "2020-01-31",
      "has_results": false,
      "last_update_posted_date": "2019-07-01",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03783728"
    },
    {
      "nct_id": "NCT02024867",
      "title": "Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skin Disease, Bacterial",
        "Abscess"
      ],
      "interventions": [
        {
          "name": "Trimethoprim-Sulfamethoxazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lucy Holmes, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Months to 17 Years"
      },
      "enrollment_count": 249,
      "start_date": "2010-02",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2015-10-19",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02024867"
    },
    {
      "nct_id": "NCT00023413",
      "title": "TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Rifabutin",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "1999-11",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2012-06-05",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023413"
    },
    {
      "nct_id": "NCT07077213",
      "title": "18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "18F-FAPI-74",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-03-12",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07077213"
    },
    {
      "nct_id": "NCT00140309",
      "title": "TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "moxifloxacin (with isoniazid, rifampin, pyrazinamide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2003-07",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2007-03-19",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00140309"
    },
    {
      "nct_id": "NCT03788434",
      "title": "Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Infection Recurrence",
        "Clostridium Difficile Infection",
        "Clostridium Difficile",
        "Clostridioides Difficile Infection Recurrence",
        "Clostridioides Difficile Infection",
        "Clostridioides Difficile",
        "CDI"
      ],
      "interventions": [
        {
          "name": "VE303",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vedanta Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2019-02-08",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03788434"
    },
    {
      "nct_id": "NCT01571414",
      "title": "Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "PA-824",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz (EFV)",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/Ritonavir (LPV/r)",
          "type": "DRUG"
        },
        {
          "name": "Rifampin (RIF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2012-05",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-10-29T07:30:45.364Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01571414"
    }
  ]
}